Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 525

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update

Open access
Rouprêt, Morgan, Seisen, Thomas, Birtle, Alison J., Capoun, Otakar, Compérat, Eva M., Dominguez-Escrig, José L., Gürses Andersson, Irene, Liedberg, Fredrik, Mariappan, Paramananthan, Hugh Mostafid, A., Pradere, Benjamin, van Rhijn, Bas W.G., Shariat, Shahrokh F., Rai, Bhavan P., Soria, Francesco, Soukup, Viktor, Wood, Robbert G., Xylinas, Evanguelos N., Masson-Lecomte, Alexandra, Gontero, Paolo·2023·European Urology

Abstract

CONTEXT The European Association of Urology (EAU) guidelines panel on upper urinary tract urothelial carcinoma (UTUC) has updated the guidelines to aid clinicians in evidence-based management of UTUC. OBJECTIVE To provide an overview of the EAU guidelines on UTUC as an aid to clinicians. EVIDENCE ACQUISITION The recommendations provided in these guidelines are based on a review of the literature via a systematic search of the PubMed, Ovid, EMBASE, and Cochrane databases. Data were searched using the following keywords: urinary tract cancer, urothelial carcinomas, renal pelvis, ureter, bladder cancer, chemotherapy, ureteroscopy, nephroureterectomy, neoplasm, (neo)adjuvant treatment, instillation, recurrence, risk factors, metastatic, immunotherapy, and survival. The results were assessed by a panel of experts. EVIDENCE SYNTHESIS Even though data are accruing, for many areas there is still insufficient high-level evidence to provide strong recommendations. Patient stratification on the basis of histology and clinical examination (including imaging) and assessment of patients at risk of Lynch syndrome will aid management. Kidney-sparing management should be offered as a primary treatment option to patients with low-risk UTUC and two functional kidneys. In particular, for patients with high-risk or metastatic UTUC, new treatment options have become available. In high-risk UTUC, platinum-based chemotherapy after radical nephroureterectomy, and adjuvant nivolumab for unfit or patients who decline chemotherapy, are options. For metastatic disease, gemcitabine/carboplatin chemotherapy is recommended as first-line treatment for cisplatin-ineligible patients. Patients with PD-1/PD-L1-positive tumours should be offered a checkpoint inhibitor (pembrolizumab or atezolizumab). CONCLUSIONS These guidelines contain information on the management of individual patients according to the current best evidence. Urologists should take into account the specific clinical characteristics of each patient when determining the optimal treatment regimen according to the risk stratification of these tumours. PATIENT SUMMARY Cancer of the upper urinary tract is rare, but because 60% of these tumours are invasive at diagnosis, timely and appropriate diagnosis is most important. A number of known risk factors exist.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2023.03.013

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 525

Metadata

Authors
Rouprêt, M., Seisen, T., Birtle, A. J., Capoun, O., Compérat, E. M., Dominguez-Escrig, J. L., Gürses Andersson, I., Liedberg, F., Mariappan, P., Hugh Mostafid, A., Pradere, B., van Rhijn, B. W. G., Shariat, S. F., Rai, B. P., Soria, F., Soukup, V., Wood, R. G., Xylinas, E. N., Masson-Lecomte, A., & Gontero, P.
Venue
European Urology
Publisher
Elsevier BV
Published
2023-07
Volume
84
Issue
1
Pages
49-64
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4360830375
Cited by
525
References
68
FWCI
125.69
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. https://app.cochat.ai/papers/10.1016/j.eururo.2023.03.013
The paper
Rouprêt, M., Seisen, T., Birtle, A. J., Capoun, O., Compérat, E. M., Dominguez-Escrig, J. L., Gürses Andersson, I., Liedberg, F., Mariappan, P., Hugh Mostafid, A., Pradere, B., van Rhijn, B. W. G., Shariat, S. F., Rai, B. P., Soria, F., Soukup, V., Wood, R. G., Xylinas, E. N., Masson-Lecomte, A., & Gontero, P. (2023). European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. European Urology. https://doi.org/10.1016/j.eururo.2023.03.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.